Editas Medicine Inc (EDIT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $334.92M
Last updated: Nov 17, 2026 at 4:26 PM ET
Editas Medicine Inc (EDIT) Stock Chart
Editas Medicine (EDIT) has a latest price of $1.82 on Nov 17, 2026, 53.7% below its 52-week high of $3.94. Its price fell 29.8% over the past 12 months. The month-end price fell 81.1% over the 10 years through Oct 2026, a compound annual decline of 15.4%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $70.11 in Dec 2020 and its lowest $1.16 in Mar 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart EDIT with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for EDIT.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 43.8%, and over 6 months it fell 25.8%. The month-end price fell 60.0% over the 3 years through Oct 2026, a compound annual decline of 26.3%.
| Period | Change |
|---|---|
| 1 month | -24.6% |
| 3 months | -43.8% |
| 6 months | -25.8% |
| 12 months | -29.8% |
| 12 months, with dividends | -29.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -60.0% | -26.3% |
| 5 years | -92.7% | -40.8% |
| 10 years | -81.1% | -15.4% |
Price by Year
Its best calendar year was 2020, when the price rose 136.8%, and its weakest was 2024, when it fell 87.5%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $2.67 | +30.2% |
| 2025 | $2.05 | +61.4% |
| 2024 | $1.27 | -87.5% |
| 2023 | $10.13 | +14.2% |
| 2022 | $8.87 | -66.6% |
| 2021 | $26.55 | -62.1% |
| 2020 | $70.11 | +136.8% |
| 2019 | $29.61 | +30.2% |
| 2018 | $22.75 | -26.0% |
| 2017 | $30.73 | +89.3% |
Trading Range
The price is 29.3% below its 50-day average of $2.58 and 32.4% below its 200-day average of $2.70.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.82 | |
| 52-week high | $3.94 | -53.7% |
| 52-week low | $1.66 | +9.9% |
| 50-day average | $2.58 | -29.3% |
| 200-day average | $2.70 | -32.4% |
Price Risk
Over 3 years, its largest fall from a peak was 91.2%.
| Measure | Value |
|---|---|
| 1-year beta | 2.36 |
| Largest fall, 1 year | -51.3% |
| Largest fall, 3 years | -91.2% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About EDIT
What is EDIT's 1-year price change?
Editas Medicine's price fell 29.8% over the past 12 months. With dividends included, the 12-month total return was -29.8%.
What is EDIT's 5-year price change?
Editas Medicine's month-end price fell 92.7% over the 5 years through Oct 2026, a compound annual decline of 40.8%. These figures leave out dividends.
What is EDIT's 52-week high and low?
Editas Medicine's 52-week high is $3.94 and its 52-week low is $1.66. Its latest price of $1.82 on Nov 17, 2026 is 53.7% below the high.
What is EDIT's beta?
Editas Medicine's 1-year beta against the S&P 500 is 2.36, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 51.3%.
Is the EDIT chart free?
Yes. Advanced Charting for EDIT is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
EDIT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors